Therefore, standard care plus radioligand therapy with 177Lu -PSMA-617 as a combination therapy significantly prolonged the imaging-based progression-free survival and overall survival of patients with PSMA-positive, metastatic, castration-resistant prostate cancer. Here, FOLH1 is linked to prostate cancer.